Compare TLS & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TLS | ACIU |
|---|---|---|
| Founded | 1969 | 2003 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 358.0M | 247.6M |
| IPO Year | 2020 | 2015 |
| Metric | TLS | ACIU |
|---|---|---|
| Price | $4.09 | $2.83 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 2 |
| Target Price | $7.90 | ★ $10.00 |
| AVG Volume (30 Days) | ★ 676.8K | 128.3K |
| Earning Date | 05-11-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 31.51 | N/A |
| EPS | ★ 0.03 | N/A |
| Revenue | ★ $164,805,000.00 | N/A |
| Revenue This Year | $18.72 | $706.75 |
| Revenue Next Year | $14.62 | $321.13 |
| P/E Ratio | $136.67 | ★ N/A |
| Revenue Growth | ★ 52.21 | N/A |
| 52 Week Low | $3.79 | $2.10 |
| 52 Week High | $8.36 | $4.00 |
| Indicator | TLS | ACIU |
|---|---|---|
| Relative Strength Index (RSI) | 41.64 | N/A |
| Support Level | $3.93 | N/A |
| Resistance Level | $4.67 | N/A |
| Average True Range (ATR) | 0.21 | 0.00 |
| MACD | -0.05 | 0.00 |
| Stochastic Oscillator | 15.77 | 0.00 |
Telos Corp offers technology solutions and services that empower and protect the world's security-conscious organizations. The company delivers efficient, adaptable, and secure solutions that protect people, organizations, and information across government and industry. The company conducts its business through two reportable and operating segments: Security Solutions and Secure Networks. The Security Solutions segment is focused on cybersecurity, cloud, and identity solutions, and secure messaging through Xacta, Telos AMHS, and Telos ID offerings. The Secure Networks segment provides secure networking architectures and solutions to customers through secure mobility solutions, network management, and defense services. The majority of revenue is from Secure Networks.
AC Immune SA is a clinical stage biopharmaceutical company advancing a portfolio of programs strategically focused on pioneering Precision Medicine for neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company has one segment. The company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.